Association of Hippo Signalling Pathway with Epigenetic Changes in Cancer Cells and Therapeutic Approaches: A Review

Author(s): Roza Motavalli, Faroogh Marofi, Maryam Nasimi, Mehdi Yousefi, Farhad M. Khiavi*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 21 , Issue 12 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Hippo signalling pathway that is evolutionarily conserved affects diver’s pathology and physiology processes, including tissue repair, wound healing, tissue size and tissue regeneration. Epigenetic changes are post-translational modifications in DNA proteins and histones. Epigenetic changes including histone acetylation and deacetylation, miRNAs dysregulation, and aberrant DNA methylation, inflammatory genes actives abnormal in Hippo signaling pathway. Using some treatments, including Histone Deacetylases (HDACs), herbal composition, siRNAs and long non-coding RNA (lncRNA) for suppressing cancer cells by targeting Hippo pathways, may open new views in cancer target therapy fields. The aim of this review study is firstly to demonstrate the importance of Hippo signalling and its association with epigenetic changes in cancer and then to demonstrate progress in targeting Hippo signalling in cancer therapy.

Keywords: Hippo signalling, cancer cell, tissue regeneration, HDACs, lncRNA, DNA methylation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 29 October, 2020
Page: [1520 - 1528]
Pages: 9
DOI: 10.2174/1871520620666201029112551
Price: $65

Article Metrics

PDF: 178